Vedanta Biosciences develops drugs based on bacterial consortia (groups of bacteria working together) to treat diseases. Using a proprietary discovery platform, the company identifies beneficial bacteria and designs rational consortia with optimized therapeutic activity, which can colonize the human intestine. The drugs are produced under CGMP standards for commercial-scale manufacturing. Unlike many biotech efforts that focus on single strains, Vedanta emphasizes defined bacterial consortia and scalable production to bring microbiome therapies to patients. Its goal is to develop and commercialize microbiome-based drugs that provide new treatment options for a range of diseases.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$434.7M
Headquarters
Cambridge, Massachusetts
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?